The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck

Table 2

Cetuximab in the curative setting.

Study	Year	Phase	Number of Patients/agent	Response (%)/Survival (months)
Cetuximab + radiation therapy
Bonner et al. [18, 19]	2006; 2010	III	𝑛=424	3 yr PFS 42 versus 31*
				3 yr OS 55 versus 45*
				5 yr OS 45.6 versus 36.4*
Cetuximab + chemoradiation
Pfister et al. [20]	2006	II	𝑛=22; cisplatin	CR 13
				PR 81
				SD 0
				DCR 94
				3 yr PFS 56
				3-yr OS 76
Langer et al. [21] (ECOG 3303)	2008	II	𝑛=61; platinum therapy	CR 23
				PR 25
				SD 31
				DCR 79
Merlano et al. [22]	2011	II	𝑛=45; cisplatin	CR 71
				PR 20
				SD 0
				DCR 94
Ang et al. [23] (RTOG 0522)	2011	III	𝑛=895; cisplatin	2 yr PFS 63 versus 64
				2 yr OS 83 versus 80

CR: complete response, PR: partial response, SD: stable disease, DCR: disease control rate (CR + PR + SD), PFS: progression-free survival, and OS: overall survival; *statistically significant.